Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
Public ClinicalTrials.gov record NCT02264990. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
Study identification
- NCT ID
- NCT02264990
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 595 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Paclitaxel Drug
- Pemetrexed Drug
- Veliparib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2014
- Primary completion
- Nov 13, 2019
- Completion
- Feb 20, 2020
- Last update posted
- Feb 25, 2021
2014 – 2020
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute /ID# 131434 | Huntsville | Alabama | 35805 | — |
| University of South Alabama /ID# 131518 | Mobile | Alabama | 36617 | — |
| Highlands Oncology Group /ID# 131250 | Springdale | Arkansas | 72762 | — |
| CBCC Global Research, Inc. at /ID# 132709 | Bakersfield | California | 93309 | — |
| California Cancer Assoc. R&E /ID# 131392 | Encinitas | California | 92024 | — |
| California Cancer Assoc. R&E /ID# 131949 | Encinitas | California | 92024 | — |
| LA Hem-Oncology Med Group /ID# 131639 | Los Angeles | California | 90017 | — |
| St Jude Hospital dba St Joseph /ID# 132943 | Santa Rosa | California | 95403 | — |
| Icri /Id# 132942 | Whittier | California | 90603 | — |
| University of Florida - Archer /ID# 132408 | Gainesville | Florida | 32610 | — |
| NorthShore University HealthSystem - Evanston Hospital /ID# 130200 | Evanston | Illinois | 60201 | — |
| Goshen Center for Cancer Care /ID# 130216 | Goshen | Indiana | 46526 | — |
| University of Louisville /ID# 130217 | Louisville | Kentucky | 40202 | — |
| Cancer Center of Acadiana /ID# 133611 | Lafayette | Louisiana | 70503 | — |
| Henry Ford Health System /ID# 130234 | Detroit | Michigan | 48202 | — |
| Herbert Herman Cancer Center /ID# 130239 | Lansing | Michigan | 48912 | — |
| Washington University-School of Medicine /ID# 131651 | St Louis | Missouri | 63110 | — |
| MD Anderson Cancer Center at Cooper - Camden /ID# 131490 | Camden | New Jersey | 08103 | — |
| Gabrail Cancer Center Research /ID# 130205 | Canton | Ohio | 44718 | — |
| Univ Oklahoma HSC /ID# 132888 | Oklahoma City | Oklahoma | 73104 | — |
| Albert Einstein Medical Center /ID# 134498 | Philadelphia | Pennsylvania | 19141 | — |
| Allegheny General Hospital /ID# 134049 | Pittsburgh | Pennsylvania | 15212 | — |
| The Jones Clinic, PC /ID# 130215 | Germantown | Tennessee | 38138 | — |
| UT Southwestern Medical Center /ID# 130236 | Dallas | Texas | 75390-7208 | — |
| Univ Texas HSC San Antonio /ID# 132972 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02264990, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2021 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02264990 live on ClinicalTrials.gov.